The Evolution of Regenerative Therapies for Neuropathy

Regenerative approaches to peripheral neuropathy have progressed from early neurotrophin trails to today’s cell and biomaterials-based strategies. While symptom control remains the clinical standard, research over the past three decades has steadily shifted toward therapies aiming to repair or replace damaged neural tissue.

Neurotrophins Show Promise

Recombinant human nerve growth factor (rhNGF) was among the first regeneration candidates. Early work reported improvements in sensory measures after months of treatment. In a large Phase 3 trial in diabetic poluneuropathy failed to confirm benefit and highlighted dose-limiting side effects.

Tissue Engineering Matures

Parallel advances in peripheral nerve repair produced bioengineered nerve guidance conduits (NGCs) and scaffold technologies to bridge nerve gaps and support axonal regrowth.

Stem Cells and the Paracrine Era

Mesenchymal stem/ stromal cells (MSCs) became a leading candidate for diabetic peripheral neuropathy (DPN) based on multipotency, immunomodulation, angiogensis, and trophic support.

A key insight is that much of MSCs’ benefit appears paracrine, shifting attention to cell-free products such as exosomes.

Clinically

Despite this momentum, major guidelines still emphasize symptom management and neuromodulatory options for painful DPN. No regenerative therapy yet has strong Phase 3 evidence leading to routine clinical adoption for reversing common neuropathies. This shows that it reduces pain rather than repairing nerve damage.

The Future

 Active lines of investigation include:

1. Optimized MSC sources and delibery routes
2. Standardized, GMP grade exosome preparations
3. Hybrid approaches combining cell/ exosome therapy with bioactive scaffolds.
   
   

Conclusion

Regenerative neuropathy care has evolved from neurotrophin hopes to sophisticated cell, exosome, and tissue-engineered strategies. Preclinical and early clinical signicals are encouraging, but disease-modifying regeneration remains an investigation.